Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261071 | 1.00 | ECE1 (0.40) | ECE1ALOX15MMP1MMP2MMP3 | |
| SCHEMBL29697562 | 0.88 | ALOX15 (0.44) | ECE1ALOX15MMP2CA1CA2 | |
| SCHEMBL7355950 | 0.86 | NOD1 (0.40) | ECE1ALOX15CA1CA2 | |
| SCHEMBL30089038 | 0.86 | ECE1 (0.44) | ECE1ALOX15CA1CA2 | |
| SCHEMBL8728335 | 0.86 | GPR84 (0.33) | ECE1ALOX15MMP1MMP2MMP3 | |
| SCHEMBL23831532 | 0.85 | EPHX1 (0.42) | ALOX15 | |
| SCHEMBL1045359 | 0.85 | EPHX1 (0.42) | ALOX15 | |
| SCHEMBL1045358 | 0.85 | EPHX1 (0.42) | ALOX15 | |
| SCHEMBL29364715 | 0.85 | EPHX1 (0.42) | ALOX15 | |
| SCHEMBL2692730 | 0.85 | EPHX1 (0.42) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0831066-A1 | Biodegradable Aspartic acid polymers for preventing scale formation in boilers | NALCO CHEMICAL COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| US-20100151501-A1 | Forms of Prostate Specific Antigens and Methods for their Detection | HYBRITECH INCORPORATED | 2010-06-17 | — | — | US | disclosed |
| US-7659073-B2 | Forms of prostate specific antigens and methods for their detection | HYBRITECH INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1392719-B1 | FORMS OF PROSTATE SPECIFIC ANTIGENS AND METHODS FOR THEIR DETECTION | HYBRITECH INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-0981629-B1 | FORMS OF PROSTATE SPECIFIC ANTIGEN AND METHODS FOR THEIR DETECTION | HYBRITECH INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7288636-B2 | Forms of prostate specific antigens and methods for their detection | HYBRITECH INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1175619-B1 | METHOD TO DISTINGUISH PROSTATE CANCER FROM BENIGN PROSTATIC HYPERPLASIA | HYBRITECH INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1392719-A4 | FORMS OF PROSTATE SPECIFIC ANTIGENS AND METHODS FOR THEIR DETECTION | HYBRITECH INC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1392719-A2 | FORMS OF PROSTATE SPECIFIC ANTIGENS AND METHODS FOR THEIR DETECTION | Hybritech Incorporated (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030166036-A1 | Protease and an aminopeptidase associated with development of benign prostatic hyperplasia (BPH) | HYBRITECH INCORPORATED | 2003-09-04 | — | — | US | disclosed |
| US-6423503-B1 | DIAGNOSING BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER; OBTAIN SAMPLE OF PROSTATE TISSUE, MONITOR CONCENTRATION OF PROSTATE SPECIFIC ANTIGEN, COMPARE TO CONTROL TISSUE OF BOTH BENIGN PROSTATE HYPERPLASIA AND PROSTATE CANCER | HYBRITECH INCORPORATED | 2002-07-23 | — | — | US | disclosed |
| US-20020058291-A1 | Forms of prostate specific antigens and methods for their detection | HYBRITECH INCORPORATED | 2002-05-16 | — | — | US | disclosed |
| US-20020045198-A1 | Forms of prostate specific antigens and methods for their detection | HYBRITECH INCORPORATED | 2002-04-18 | — | — | US | disclosed |
| EP-1175619-A1 | METHOD TO DISTINGUISH PROSTATE CANCER FROM BENIGN PROSTATIC HYPERPLASIA | Hybritech Incorporated (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1173556-A1 | FORMS OF PROSTATE SPECIFIC ANTIGEN (PSA) SPECIFIC FOR BENIGN PROSTATIC HYPERPLASIA (BPH) AND METHODS OF USING SUCH | Hybritech Incorporated (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066718-A1 | FORMS OF PROSTATE SPECIFIC ANTIGEN (PSA) SPECIFIC FOR BENIGN PROSTATIC HYPERPLASIA (BPH) AND METHODS OF USING SUCH | HYBRITECH INCORPORATED (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000067030-A1 | METHOD TO DISTINGUISH PROSTATE CANCER FROM BENIGN PROSTATIC HYPERPLASIA | HYBRITECH INCORPORATED (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-0981629-A1 | FORMS OF PROSTATE SPECIFIC ANTIGEN AND METHODS FOR THEIR DETECTION | HYBRITECH INCORPORATED (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998049323-A1 | FORMS OF PROSTATE SPECIFIC ANTIGEN AND METHODS FOR THEIR DETECTION | HYBRITECH INCORPORATED (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5260060-A | Dissolving blood clots, anticoagulant, metalloproteinase | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-11-09 | — | — | US | disclosed |